Vesalius Biocapital Partners
Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007.
Business Model:
Revenue: $9.8M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Vesalius Biocapital Partners Information
Geographic Data
Address: 1B rue Thomas Edison
City: Strassen
State: luxembourg
Zip: 1445
Country: LU
Financial Info
Stage:
Raised Last:
$0
Raised Total:$209M
Social
Facebook
Linkedin
Crunchbase
Metrics
7,870,244Website Global Rank
420Website Monthly Traffic
Twitter Followers
Description
Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception. With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financing rounds. Their companies are based in Europe allowing easy interaction with management. They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2018 | OMEICOS Therapeutics | Series C | 0 |
| 1/2013 | FF Pharma | Series A | 5.3M |
| 7/2019 | DEARhealth | Series A | 6.8M |
| 7/2008 | Genomic Vision | Series B | 6.3M |
| 4/2018 | Sword Health | Seed Round | 0 |
| 2/2010 | Promethera Biosciences | Series A | 7.3M |
| 2/2022 | Memo Therapeutics | Series B | 0 |
| 1/2017 | Exact Imaging | Series C | 16.3M |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 3/2022 | Scenic Biotech | Series A | 0 |
| 9/2011 | Amakem | Series A | 25.2M |
| 10/2008 | Trinean | Venture Round | 4.7M |
| 11/2014 | Humedics | Series C | 7.8M |
| 10/2015 | Ogeda | Series B | 17.9M |
| 11/2012 | Ogeda | Private Equity Round | 13M |
| 3/2017 | OMEICOS Therapeutics | Series B | 0 |
| 1/2020 | Mecuris | Series B | 0 |
| 10/2013 | TROD Medical | Series B | 6.6M |
| 6/2010 | Complix | Series A | 6.2M |
| 7/2019 | Forendo Pharma | Venture Round | 0 |
| 9/2015 | Apitope | Series B | 0 |
| 10/2021 | Rejuvenate Biomed | Series B | 0 |
| 3/2021 | Rejuvenate Biomed | Series A | 0 |
| 6/2013 | Complix | Series B | 15.6M |
| 8/2011 | ProFibrix | Series B | 10.6M |
| 1/2015 | Genkyotex | Post-IPO Equity | 0 |
| 4/2012 | Trinean | Venture Round | 0 |
| 5/2011 | Genkyotex | Series C | 20.4M |
| 7/2012 | Genkyotex | Series C | 25.6M |
| 11/2022 | CatalYm | Series C | 0 |
| 11/2020 | Catalym | Series B | 59.3M |
| 1/2019 | Mecuris | Series A | 0 |
| 10/2016 | Promethera Biosciences | Series C | 10.9M |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 11/2017 | Ncardia | Series B | 12.4M |
| 2/2020 | OncoDNA | Series B | 0 |
| 8/2019 | Tonic App | Series A | 3.9M |
| 1/2021 | Sword Health | Series B | 0 |
| 2/2020 | Sword Health | Series A | 0 |
| 9/2018 | Forendo Pharma | Venture Round | 0 |
| 4/2015 | OMEICOS Therapeutics | Series A | 0 |
| 9/2021 | Caresyntax | Series C | 130M |
| 8/2019 | Tonic App | Venture Round | 3.9M |
| 10/2008 | Apitope | Series A | 12.9M |
| 11/2009 | Activaero | Series A | 15.8M |
| 2/2011 | Activaero | Series A | 0 |
| 10/2014 | Ncardia | Series A | 5.1M |
| 3/2022 | Scenic Biotech | Series A | 0 |
| 2/2022 | Memo Therapeutics | Series B | 0 |
| 10/2021 | Rejuvenate Biomed | Series B | 0 |
| 9/2021 | Caresyntax | Series C | 0 |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 3/2021 | Rejuvenate Biomed | Series A | 0 |
| 1/2021 | Sword Health | Series B | 0 |
| 11/2020 | Catalym | Series B | 0 |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 2/2020 | Sword Health | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
